50% off Premium Yearly

TSE:ZUH
This summary was created by AI, based on 1 opinions in the last 12 months.
The BMO EqWt US HthCare Hedged CAD (ZUH-T) is highly regarded due to its equal-weight strategy, which effectively mitigates concentration risks associated with mega-pharmaceutical firms. Operating within the pharmaceutical, biotech, and healthcare services sectors, it is characterized by lower volatility, making it a viable diversifier against the concentrated leadership seen in current market indices. The defensive growth nature of this sector is particularly appealing as it tends to exhibit steady demand, reinforced by companies maintaining strong balance sheets and low sensitivity to economic fluctuations. Furthermore, the anticipated surge in healthcare innovation powered by AI presents a substantial growth opportunity, positioning this investment favorably. It is important to note that while the expert manages exposure for clients through the futures market and does not directly own the ETF, he emphasizes the strategic benefits of this approach.
This has more health care in it, rather than pharmaceuticals. FT AlphaDEX US Health Care (FHH-T) is a rule based ETF in the healthcare area, but they use the Russell 1000, drilling down a little bit more into some of the smaller and less recognizable companies. With this one he is not buying a US health care with an impoverished Cdn$.
US healthcare is one area that hasn’t been on people’s radar for quite a while but has been performing pretty well. Healthcare is typically one or 2 products that really drive the earnings of each company. This is an equal weighted ETF, so regardless of which company does well, as long as the overall sector does well it should do well.
He likes this because it is equal weighted and hedged against the decline in the US$. You can quite comfortably put this into your portfolio.